Updated Efficacy/Safety Results of MajesTEC-1 (Teclistamab) at ASCO 2022
Dr. Ajay Nooka Discusses Updated Efficacy/Safety Results of MajesTEC-1 (Teclistamab) in RRMM Patients
Abstract Title:
Teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): Updated efficacy and safety results from MajesTEC-1.
What is the purpose of this trial?
The multicohort, open-label, phase 1/2 MajesTEC-1 study is investigating safety/efficacy of teclistamab in relapsed/refractory multiple myeloma (RRMM) patients who previously received ≥3 lines of therapy (LOT). The purpose of this study is to evaluate the efficacy of teclistamab at the recommended Phase 2 dose (RP2D). Updated results from patients treated at the RP2D, including additional patients and longer follow-up are presented.
In this video:
Dr. Ajay Nooka (Emory University School of Medicine, Winship Cancer Institute—Atlanta, GA) discusses updated efficacy/safety results of MajesTEC-1 (Teclistamab) in RRMM patients
Conclusion:
Current data with ̃9 months of follow-up reaffirm the deep and durable responses that have been observed with teclistamab in patients with highly refractory multiple myeloma (HRMM), with no new safety signals. Additional data with longer follow-up, including subgroup analyses and progression-free survival (PFS) will be presented.
Clinical trial information: NCT04557098
Doctor Bio:
Ajay Kumar Nooka, MD, MPH, FACP, is an Associate Professor and serves as director of the Myeloma Program in the Department of Hematology and Medical Oncology at Emory University School of Medicine. He also serves as medical director of the Winship Data and Technology Applications Shared Resource at Winship Cancer Institute of Emory University. An Emory Healthcare network physician since 2011, Dr. Nooka is a board-certified hematologist specializing in the treatment of patients with multiple myeloma.
with support from:
Bristol Myers Squibb, Janssen, and Takeda Oncology